Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
January 14 2020 - 1:00AM
Business Wire
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200113005846/en/
(Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the
appointment of Dr. Steven Hildemann as Executive Vice President,
Chief Medical Officer, Head of Global Medical Affairs and
Pharmacovigilance effective March 1, 2020. Based in Paris, France,
Dr. Hildemann will report directly to Aymeric Le Chatelier, CEO,
Ipsen and serve on the Executive Leadership Team.
Aymeric Le Chatelier, CEO, Ipsen, commented, “As we advance as a
leading global biopharmaceutical company focused on innovation and
Specialty Care, it is my great pleasure to appoint Dr. Hildemann to
lead Ipsen’s Global Medical Affairs, Patient Affairs and
Pharmacovigilance organizations through patient-centric leadership,
sound medical governance and business conduct. With over 20 years
of service in the pharmaceutical industry and 10 years as a
physician-scientist in academic medicine, he brings a wealth of
experience in medical affairs, clinical operations and patient
safety from major global biopharmaceutical companies. Dr. Hildemann
will play a crucial role in delivering on our global medical and
patient safety strategy, engaging in structured, ethical and
high-quality dialogue with patients, external and internal
stakeholders throughout the entire life-cycle of Ipsen’s
portfolio.”
Dr. Hildemann will act as a strategic partner to Ipsen’s
scientific, clinical and business teams. He will provide a global
medical strategy based on real value to patients and caregivers. In
close partnership with R&D, Dr. Hildemann will lead the
generation of post-launch clinical trial data by defining,
prioritizing, optimizing or guiding studies in line with this
strategy. As a member of the Executive Leadership team, he will
actively contribute to the overall management and strategic
leadership of the company.
Prior to joining Ipsen, Dr. Hildemann held leadership roles in
science-based bioethics and built an innovative digital health
startup in cancer care after serving for five years as Chief
Medical Officer, Senior Vice President, Head of Global Medical
Affairs and Global Patient Safety at Merck. He also held several
strategic leadership positions with biopharmaceutical companies
such as Pharmacia-Pfizer and Schering-Plough-MSD. Dr Hildemann is
board certified in internal medicine and cardiology with broad
clinical training across internal medicine including medical
oncology, gastroenterology, rheumatology and pulmonary oncology at
university hospitals in Munich, Germany. Throughout his career, he
has engaged in part-time clinical practice, late-stage
pharmaceutical research and medical teaching. Dr. Hildemann
received his MD-PhD at the Albert Ludwig University of Freiburg,
Germany, where he continues to serve as an adjunct Professor of
Medicine.
About Ipsen Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and Specialty Care.
The Group develops and commercializes innovative medicines in three
key therapeutic areas – Oncology, Neuroscience and Rare Diseases.
Its commitment to oncology is exemplified through its growing
portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has
a well-established Consumer Healthcare business. With total sales
over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over
115 countries, with a direct commercial presence in more than 30
countries. Ipsen’s R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay,
France; Oxford, UK; Cambridge, US). The Group has about 5,800
employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and
in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on
Ipsen, visit www.ipsen.com.fr
Ipsen—Cautionary Note Regarding Forward-Looking
Statements The forward-looking statements, objectives and
targets contained herein are based on the Group’s management
strategy, current views and assumptions. Such statements involve
known and unknown risks and uncertainties that may cause actual
results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group’s
future ability to achieve its financial targets, which were set
assuming reasonable macroeconomic conditions based on the
information available today. Use of the words "believes",
"anticipates" and "expects" and similar expressions are intended to
identify forward-looking statements, including the Group’s
expectations regarding future events, including regulatory filings
and determinations. Moreover, the targets described in this
document were prepared without taking into account external growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by the Group. These targets
depend on conditions or facts likely to happen in the future, and
not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising product
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might
face competition from generic products that might translate into a
loss of market share. Furthermore, the Research and Development
process involves several stages each of which involves the
substantial risk that the Group may fail to achieve its objectives
and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot
be certain that favorable results obtained during pre-clinical
trials will be confirmed subsequently during clinical trials, or
that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the product concerned.
There can be no guarantees a product will receive the necessary
regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic
factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and
health care legislation; global trends toward health care cost
containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the Group's
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions. The Group also
depends on third parties to develop and market some of its products
which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the
Group’s activities and financial results. The Group cannot be
certain that its partners will fulfil their obligations. It might
be unable to obtain any benefit from those agreements. A default by
any of the Group’s partners could generate lower revenues than
expected. Such situations could have a negative impact on the
Group’s business, financial position or performance. The Group
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. The
Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés
Financiers. The risks and uncertainties set out are not exhaustive
and the reader is advised to refer to the Group’s 2018 Registration
Document available on its website (www.ipsen.com).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200113005846/en/
Media Christian Marcoux Senior Vice President,
Global Communications +33 (0)1 58 33 67 94
Christian.marcoux@ipsen.com
Fanny Allaire Director, Ipsen France Hub, Global
Communications +33 (0) 1 58 33 58 96 Fanny.allaire@ipsen.com
Financial Community Eugenia Litz Vice President,
Investor Relations +44 (0) 1753 627721 Eugenia.litz@ipsen.com
Myriam Koutchinsky Investor Relations Manager +33 (0)1 58
33 51 04 Myriam.koutchinsky@ipsen.com
Ipsen (EU:IPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Apr 2023 to Apr 2024